| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nektar Therapeutics (NKTR) has 8 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. NKTR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 75.9K | $4.99M | - | |
| Other | 21.6K | $1.42M | - | |
| Other | 15.4K | $1.01M | -5,538 | |
| Dir | 8.0K | $525.6K | - | |
| Dir | 8.0K | $525.6K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 16, 2022 | Labrucherie Gil M84 | SVP, COO &CFO | Sell | 17,448 | $3.95 | $68,919.60 | -5.3% | +26.5% | -81.6% | |
| Feb 16, 2022 | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 10,912 | $10.95 | $119,486.40 | -3.8% | -64.8% | -73.4% | |
| Feb 16, 2022 | Wilson Mark Andrew58 | SVP &General Counsel | Sell | 3,661 | $10.95 | $40,087.95 | -2.9% | -64.8% | -73.4% | |
| Feb 16, 2022 | Thomsen Jillian B.86 | SVP &Chief Accounting Officer | Sell | 2,363 | $10.95 | $25,874.85 | -1.4% | -64.8% | -73.4% | |
| Feb 16, 2022 | Robin Howard W58 | President &CEO | Sell | 12,480 | $10.95 | $136,656.00 | -2.1% | -64.8% | -73.4% | |
| Feb 16, 2022 | Northcott John79 | SVP &Chief Commercial Officer | Sell | 4,852 | $10.95 | $53,129.40 | -2.1% | -64.8% | -73.4% | |
| Feb 16, 2022 | Labrucherie Gil M84 | SVP, COO &CFO | Sell | 7,579 | $10.95 | $82,990.05 | -2.5% | -64.8% | -73.4% | |
| Nov 18, 2021 | Labrucherie Gil M84 | SVP, COO &CFO | Sell | 24,149 | $13.10 | $316,390.84 | -4.5% | -4.8% | -70.3% | |
| Nov 16, 2021 | Northcott John79 | SVP &Chief Commercial Officer | Sell | 6,061 | $13.16 | $79,762.76 | -3.0% | -18.3% | -73.5% | |
| Nov 16, 2021 | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 20,869 | $13.16 | $274,636.04 | -8.3% | -18.3% | -73.5% |